Lormetazepam

Evidence Level: L1

Predicted Indications: 10

Lormetazepam
Lormetazepam: From Insomnia (Undocumented Original Use) to Confirmed Insomnia Indication

## Pharmacist Assessment Report

Lormetazepam: From Insomnia (Undocumented Original Use) to Confirmed Insomnia Indication

One-Sentence Summary

Lormetazepam is a benzodiazepine hypnotic; this Evidence Pack has no recorded original indication or mechanism-of-action data (data gap), but based on established pharmacology it is already used in parts of Europe (as Noctamid) for insomnia. The TxGNN model’s top signal also points to Insomnia (disease), with 3 clinical trials and 4 publications identified — this is best read as a confirmation of an established use rather than a genuine repurposing hypothesis. Note: the Evidence Pack also flagged several lower-confidence signals (anxiety, alcohol withdrawal delirium, various “abuse” categories) that are largely unsupported (Hold) and are not covered further in this report.

Quick Overview

Item	Content
Original Indication	Not documented in this dataset (data gap — closest real-world match: insomnia, marketed in parts of Europe as Noctamid)
Predicted New Indication	Insomnia (disease)
TxGNN Prediction Score	99.98%
Evidence Level	L1
UK Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data is not available in this dataset (flagged as a High-severity data gap). Based on known pharmacology, lormetazepam is a benzodiazepine that acts as a positive allosteric modulator of the GABA-A receptor, producing sedative-hypnotic effects — the same class mechanism underlying agents such as diazepam and flunitrazepam.

Insomnia is not truly a “new” indication for lormetazepam: it is the drug’s established, originally-approved use in several European markets (brand name Noctamid), and the Evidence Pack’s empty original_indications field appears to be a data-capture gap rather than a genuine absence of prior approved use. In other words, the TxGNN signal here largely reconfirms known pharmacology rather than proposing a novel therapeutic hypothesis.

This still has practical value for a UK context: lormetazepam currently holds no UK marketing authorisation (0 licenses, “Not marketed”), so the clinical trial and literature evidence assembled here is directly relevant to any future licensing assessment for the insomnia indication specifically in the UK market, even though it would not represent a novel therapeutic use elsewhere.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00679900	Phase 3	Completed	283	Randomised, double-blind comparison of eplivanserin 5 mg/day vs lormetazepam 1 mg/day in chronic primary insomnia with sleep-maintenance difficulties; assessed next-day residual sleepiness and safety, including rebound insomnia/withdrawal.
NCT00788515	Phase 3	Terminated	33	Randomised, double-blind comparison of volinanserin 2 mg/day vs lormetazepam 1 mg/day in chronic primary insomnia; study terminated early, limiting statistical power.
NCT06473415	N/A	Recruiting	50	Observational EEG study of continuous lormetazepam infusion on sleep/sedation patterns in ICU patients — an indirect, non-randomised signal from a critical-care rather than outpatient insomnia population.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
6113175	1981	RCT	J Int Med Res	Double-blind comparison in 100 outpatients: lormetazepam 1 mg significantly outperformed diazepam 5 mg on sleep-onset latency and duration of uninterrupted sleep.
2873832	1986	Cohort	Br J Clin Pract	Cohort study of long-term nitrazepam users transferred to lormetazepam (no abstract available; title indicates a switching/tolerability study).
2883820	1986	Review	Acta Psychiatr Scand Suppl	Review of hypnotic classes for insomnia subtypes, discussing benzodiazepine pharmacokinetic/pharmacodynamic profiles including agents like lormetazepam.
11215344	2001	Review	MMW Fortschr Med	Review discussing antidepressants as an alternative sleep aid to benzodiazepines (no abstract available).

UK Market Information

Lormetazepam currently holds no UK marketing authorisation (0 licenses recorded; market status: Not marketed). No product-level data (PL number, product name, dosage form, approved indication text) is available in this dataset.

Safety Considerations

Key warnings, contraindications, and drug–drug interaction data are not available in this Evidence Pack (flagged as a Blocking-severity data gap — TFDA/MHRA-equivalent product labelling has not yet been sourced). As a class, benzodiazepines carry known risks of dependence, withdrawal/rebound insomnia, sedation, and next-day psychomotor impairment, as reflected in several of the literature items above — but drug-specific warning text should not be inferred from this alone.

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: One completed Phase 3 RCT (n=283) plus supporting Phase 3 and mechanistic/observational data give reasonable (L1) confidence that lormetazepam is effective for insomnia — but this reflects an already-established use rather than a novel repurposing opportunity, and the drug has no current UK licence or sourced safety labelling.

To proceed, the following is needed:

MHRA-equivalent SmPC (warnings, contraindications, DDI) — currently a Blocking data gap (DG001)
Confirmed mechanism-of-action documentation from DrugBank — currently a High-severity data gap (DG002)
A UK-specific licensing pathway assessment, since lormetazepam has 0 current UK marketing authorisations
Clarification of the original_indications data gap to confirm this is a labelling-confirmation exercise rather than a true repurposing candidate
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.